Potassium-Binding Polymer for RAAS-Linked Hyperkalemia Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Patients with hypertension, chronic kidney disease, and Type II diabetes mellitus, treated with renin-angiotensin-aldosterone system (RAAS) agents, face hyperkalemia and potassium retention, leading to elevated serum potassium levels and compromised kidney function, necessitating a need to control blood pressure and stabilize kidney function.
Innovation Solution
Administration of a potassium-binding agent, such as a 2-fluoroacrylate-divinylbenzene-1,7-octadiene copolymer crosslinked in salt or acid form, to manage serum potassium levels and stabilize kidney function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stress or pressure
If RAAS inhibitors are administered to treat hypertension, then blood pressure control is improved, but serum potassium levels increase (hyperkalemia)
Solution Approach 1:
A potassium-binding polymer is introduced as an intermediary substance that selectively binds potassium in the gastrointestinal tract. This polymer acts as a mediator between the RAAS inhibitor therapy and the harmful effect of hyperkalemia, allowing blood pressure control to continue while preventing potassium accumulation through direct potassium removal from the digestive system.
Solution Approach 2:
The patent extracts harmful potassium from the body through the potassium-binding polymer administered via gastrointestinal route. The polymer selectively captures and removes excess potassium from the gastrointestinal tract, separating the beneficial blood pressure effect of RAAS inhibitors from the harmful hyperkalemic effect by physically removing potassium before it can be absorbed into the bloodstream.
2Reliability
If RAAS inhibitors are administered to treat hypertension, then cardiovascular protection is improved, but kidney function deteriorates
Solution Approach 1:
The potassium-binding polymer serves as an intermediary that protects kidney function by preventing hyperkalemia-induced renal damage. While RAAS inhibitors provide cardiovascular protection through aldosterone inhibition, the polymer simultaneously prevents the potassium accumulation that would otherwise harm renal function, thus protecting both cardiovascular and renal systems.
3Object-affected harmful factors
If potassium-binding agent is administered to lower serum potassium, then hyperkalemia is treated, but blood pressure control may be compromised
Solution Approach 1:
The therapeutic approach is segmented into two independent components: RAAS inhibitors that handle blood pressure control through aldosterone inhibition, and potassium-binding polymers that handle hyperkalemia through direct potassium removal. This segmentation allows each agent to perform its specific function without interfering with the other, maintaining both blood pressure control and potassium regulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The potassium-binding agent effectively reduces serum potassium levels, lowers blood pressure, and stabilizes kidney function, reducing the risk of hyperkalemia and improving renal outcomes in patients.
Implementation Method 1
crosslinked cation exchange polymers comprising a fluoro group and an acid group... useful to bind potassium in the gastrointestinal tract
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention generally relates to methods of treating hypertension (HTN) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (CKD) or Type II diabetes mellitus (T2DM). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from CKD, T2DM or HTN and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The invention also relates to methods of treating kidney disease in a patient in need thereof, wherein the patient is optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods can comprise administering an effective amount of a potassium-binding agent to the patient to lower the patient's blood pressure and/or increase or stabilize the patient's kidney function.